Please use this identifier to cite or link to this item:
Title: Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high CTC counts.
Authors: Shaw, Jacqueline A.
Guttery, David S.
Hills, A.
Fernandez-Garcia, Daniel
Page, Karen
Rosales, B. M.
Goddard, K. S.
Hastings, Robert K.
Luo, Jinli
Ogle, O.
Woodley, L.
Ali, S.
Stebbing, J.
Coombes, R. C.
First Published: 3-Nov-2016
Publisher: American Association for Cancer Research
Citation: Clinical Cancer Research, 2016
Abstract: PURPOSE: The purpose of this study was to directly compare mutation profiles in multiple single CTCs and cfDNA isolated from the same blood samples taken from patients with metastaic breast cancer (MBC). We aimed to determine whether cell-free DNA would reflect the heterogeneity observed in 40 single CTCs. EXPERIMENTAL DESIGN: CTCs were enumerated by Cellsearch. CTC count was compared with the quantity of matched cfDNA and serum CA15-3 and alkaline phosphatase (ALP) in 112 patients with metastatic breast cancer. In 5 patients with {greater than or equal to}100 CTCs, multiple individual EpCAM-positive CTCs were isolated by DEPArray and compared with matched cfDNA and primary tumour tissue by targeted next generation sequencing (NGS) of ~2200 mutations in 50 cancer genes. RESULTS: In the whole cohort, total cfDNA levels and cell counts ({greater than or equal to}5 CTCs) were both significantly associated with overall survival, unlike CA15-3 and ALP. NGS analysis of 40 individual EpCAM-positive CTCs from 5 patients with MBC revealed mutational heterogeneity in PIK3CA, TP53, ESR1 and KRAS genes between individual CTCs. In all 5 patients cfDNA profiles provided an accurate reflection of mutations seen in individual CTCs. ESR1 and KRAS gene mutations were absent from primary tumour tissue and therefore likely reflect either a minor sub-clonal mutation or were acquired with disease progression. CONCLUSION: Our results demonstrate that cfDNA reflects persisting EpCAM-positive CTCs in patients with high CTC counts and therefore may enable monitoring of the metastatic burden for clinical decision-making.
DOI Link: 10.1158/1078-0432.CCR-16-0825
ISSN: 1078-0432
eISSN: 1557-3265
Version: Post-print
Status: Peer-reviewed
Type: Journal Article
Rights: Creative Commons “Attribution Non-Commercial No Derivatives” licence CC BY-NC-ND, further details of which can be found via the following link: Archived with reference to SHERPA/RoMEO and publisher website.
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
File Description SizeFormat 
1078-0432.CCR-16-0825.full.pdfPost-review (final submitted author manuscript)2.85 MBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.